Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.

摘要: Treatment success of chronic hepatitis C virus genotype 1 infection has improved with the advent telaprevir plus peg-interferon/ribavirin triple combination therapy. However, effect inosine triphosphatase (ITPA) polymorphism on dose reduction during therapy, especially postmarketing phase, not been sufficiently evaluated. We analysed 273 patients who were treated therapy and assessed ITPA reduction. IFNL4 SNP genotypes determined by Invader assay. A stepwise multivariate regression analysis was performed to identify factors associated outcome The overall sustained viral response (SVR) rate 12 weeks after end 80.2% (219/273). Decline haemoglobin significantly faster, ribavirin more extensively reduced in rs1127354 CC than CA/AA. Extensive resulted mild peg-interferon, but no significant increase breakthrough. Although amount given slightly higher CA/AA patients, total peg-interferon SVR did differ between two groups. Multivariate showed that genotype, platelet count adherence Postmarketing-phase a high spite extensive diverse patient population, indicating importance treatment continuation appropriate management adverse events.